Actinium Pharmaceuticals’ (ATNM) Overweight Rating Reaffirmed at Stephens

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “overweight” rating reissued by equities researchers at Stephens in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. Stephens’ price objective suggests a potential upside of 248.43% from the stock’s current price.

Several other analysts have also issued reports on the company. Maxim Group reduced their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Up 1.1 %

Shares of NYSE:ATNM traded up $0.02 on Tuesday, reaching $1.44. 185,958 shares of the company’s stock were exchanged, compared to its average volume of 444,761. Actinium Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $10.24. The company’s fifty day moving average price is $1.79. The firm has a market cap of $44.77 million, a P/E ratio of -1.03 and a beta of 0.14.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ATNM. Renaissance Technologies LLC bought a new stake in shares of Actinium Pharmaceuticals during the second quarter worth $142,000. Bank of New York Mellon Corp boosted its holdings in shares of Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares in the last quarter. Vanguard Group Inc. grew its position in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after acquiring an additional 82,113 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals in the 2nd quarter worth about $92,000. Finally, Marshall Wace LLP raised its position in Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after purchasing an additional 103,557 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).